Prime shows how carve-in wins for clients—it’s better than carve-out.

Prime’s carve-in analytics prevail in a rigorous scientific peer review.

August 21, 2020

For the first time, Prime’s puts its carve-in analytics through a rigorous scientific peer review. It’s clear. This published, peer reviewed study showed Regence and Prime carve-in pharmacy was associated with lowered overall health care costs.

Carve-out is out. This study used medical data and followed members for two years. The final cohorts consisted of 205,835 carve-in and 125,555 carve-out members.

Compared to the carve out members, members with carve-in benefits had an average:

  • $148 lower total medical cost PMPY
  • 15% lower odds of hospitalization
  • 7% lower odds of ED visit

In 5 of 7 chronic conditions, members with carve-in benefits had significant lower costs and medical event odds as shown here:

  • 12%-17% lower medical costs
  • 22%-36% lower odds of hospitalization
  • 16%-20% lower odds of ED visit

The study findings indicate that integrated, carve-in pharmacy and medical benefits are associated with lower medical costs, fewer hospitalizations, and fewer ED visits.

This study, co-authored by researchers at Prime and Regence Health Plans, is to our knowledge, the only scientifically peer-reviewed study published on the subject. The authors received a platinum award for this research, which is published in the peer-reviewed Journal of Managed Care & Specialty Pharmacy (JMCP).

Pharmacy Benefit Carve-in Versus Carve-out: Cost and Medical Events Two-year Retrospective Cohort Study (Spring 2020)

Related news

Perspectives

July 16, 2024

LISTEN NOW: Beyond the business – Stories of corporate kindness | Pharmacy Friends Podcast

In this episode, we talk about how our employees' help goes beyond our work in health care, aiding in philanthropic efforts

Perspectives

July 12, 2024

August 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

July 12, 2024

High-Cost Therapy Profile: July 2024

Detailed information about Afamitresgene autoleucel Intravenous (IV)